Abstract: A three terminal neuromorphic synaptic device and a method for manufacturing the same are provided. The three terminal neuromorphic synaptic device includes a substrate, source/drain electrodes provided on the substrate, a channel region electrically connected between the source electrode and the drain electrode, an ion transfer layer provided on the channel region, a gate electrode provided on the ion transfer layer, and a voltage application unit to apply a gate voltage to the gate electrode. The ion transfer layer includes an electrolyte material to transfer an active ion of the gate electrode between the gate electrode and the channel region, in response to the gate voltage applied to the gate electrode. The voltage application unit adjusts a resistance and a conductance of the channel region by changing an amount of active ions accumulated in the channel region, depending on the number of times that the gate voltage is applied.

Abstract: A dental liner and a manufacturing method therefor are disclosed. The dental liner is a dental liner for coupling feldspar porcelain and zirconia and includes: silicon dioxide; aluminum oxide; 1,4-butanediol for maintaining the moisture of the dental liner and preventing the generation of layers; and a zirconia powder for coupling the dental liner and zirconia by strengthening chemical bonding of the dental liner and zirconia.

Abstract: Disclosed herein an apparatus for generating hologram and a method for generating hologram using the same. The apparatus includes: a geometric phase modulator disposed to enable incident light from a target object to pass through and configured to modulate the incident light to a plurality of circular polarizations; an image sensor configured to receive the plurality of circular polarizations and to acquire an interference fringe generated by the plurality of circular polarizations as an image; and a polarization selective element equipped with a liquid crystal element, which controls an output polarization angle of the incident light according to an output polarization signal, and configured to sequentially output the incident light at output polarization angles different from each other.

Abstract: The present invention relates to a gold nanoparticle-fluorescent hybrid material with improved fluorescence intensity and stability and a method for preparing the same. More specifically, the present invention relates to a gold nanoparticle-fluorescent hybrid material including gold nanoparticles, each of which is a polyhedron surrounded by 6 quadrilaterals, carbon quantum dots, and a polyglycol linking the gold nanoparticles with the carbon quantum dots, a method for preparing the hybrid material, a biosensor using the hybrid material, and a light emitting device for a display using the hybrid material.

Abstract: The present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition including same, wherein the novel tryptophan hydroxylase inhibitor has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or cardiovascular system disorders, related to TPH1 activity. In particular, the novel tryptophan hydroxylase inhibitor has an excellent treatment effect on inflammatory bowel disorders, and thus can be usefully used for the treatment of inflammatory bowel disorder.

Abstract: The present invention relates to a composition for treating neuroinflammatory disease comprising a complement component 8 gamma protein or a fragment thereof, and more particularly, to use for treating neuroinflammatory disease of a complement component 8 gamma protein or a fragment thereof which exhibits an effect of reducing the expression of inflammatory cytokines in microglia. The composition of the present invention has effects of reducing Alzheimer's abnormal behavior patterns and reducing the secretion of neuroinflammatory cytokines in brain microglia and thus can be very usefully used for development of an agent for preventing or treating neuroinflammatory disease.

Abstract: A scintillator, a preparation method therefor, and an application thereof are disclosed wherein the scintillator has a chemical formula of TlaAbBc:yCe, wherein: A is at least one rare earth element selected from trivalent rare earth elements; B is at least one halogen element selected from halogen elements; a=1, b=2 and c=7, a=2, b=1 and c=5, or a=3, b=1 and c=6; and y is greater than or equal to 0 and less than or equal to 0.5. According to another embodiment, the scintillator has a chemical formula of TlaAbBc:yEu, wherein: A is an alkaline earth metal element; B is a halogen element; a=1, b=2 and c=5, or a=1, b=1 and c=3; and y is greater than or equal to 0 mol % and less than or equal to 50 mol %.

Abstract: A surgical navigation system according to one embodiment may comprise: an electromagnetic wave generation unit; a first detection unit attached to a surgical site of an object to detect a position attached to the surgical site; a second detection unit installed in a patient-specific surgical guide instrument inserted into the surgical site to receive the electromagnetic wave and detect the position of the patient-specific surgical guide instrument; a third detection unit installed in the surgical instrument inserted into the surgical site to detect the position of the surgical instrument; an information processing unit for registering the position of the first detection unit and the position of the third detection unit and for tracking the position of the surgical instrument on the basis of the position of the first detection unit attached to the surgical site, by setting the position of the patient-specific surgical guide instrument as a reference position when the patient-specific surgical guide instrument

Abstract: The present application relates to a method for preparing transformed yeast producing 1-octen-3-ol, and yeast prepared by the method, and is useful in the cosmetic industry and the food development industry which use a Tricholoma matsutake scent.

Abstract: A method of preventing or treating pathogenic bacterial infectious diseases, includes: providing a pharmaceutical composition comprising a LysSAP26 protein, wherein the LysSAP26 protein is a recombinant protein composed of an amino acid sequence derived from the bacteriophage genome and includes an amino acid sequence represented by SEQ ID NO: 1 as an active ingredient; and administering the pharmaceutical composition to a subject.

Abstract: The present invention relates to a ferritin nanocage for multi-displaying a TRAIL trimer and a cancer-targeting peptide, and use thereof as an anticancer agent, and relates to the development of a TRAIL fusion nanoprotein, in which TRAIL with a trimer structure is conjugated to a human ferritin monomer fragment, and which exhibits enhanced cancer targeting using a cancer-targeting peptide. When injected into a blood vessel, the fusion protein according to the present invention effectively targets cancer and thus effectively leads to cancer death caused by TRAIL, wherein the fusion nanoprotein addresses the instability and off-targeting problems of TRAIL proteins, stably delivers a TRAIL trimer to cancer tissue, and thus there is a high possibility of developing an anticancer agent using same.

Abstract: Provided are a device and a method for determining an edge location based on the adaptive weighting of gradients (AWG). The method for determining an edge location according to an embodiment of the present invention includes the steps of determining, based on the edge width of an edge profile in an image, a power factor to be applied to a gradient of the edge profile in order to determine an edge location, calculating a difference value between values of adjacent pixels in the edge profile to generate the gradient, and applying the power factor determined based on the edge width to the gradient to determine the edge location.

Abstract: The present invention relates to a novel phenylsulfonyl oxazole derivative and a use thereof and specifically, to a compound represented by Chemical Formula 1 in the present specification or a pharmaceutically acceptable salt thereof, and to a use thereof for prevention, treatment, or improvement of neurodegenerative disease.

Abstract: Disclosed is a method for producing a Heusler-based phase thermoelectric material using an amorphous phase precursor. More specifically disclosed is a method for producing a powder or bulk thermoelectric material having a microstructure including a Heusler-based phase with a thermoelectric effect by crystallization of an amorphous phase precursor prepared by a non-equilibrium processes. Also disclosed is a device using a Heusler-based phase thermoelectric material produced by the method. The method largely avoids the efficiency problems of conventional methods, including low productivity in scaling up caused by long annealing time, high annealing temperature, and contamination during nanopowder production, achieving improved process efficiency. In addition, the method enables efficient production of a thermoelectric material having a nano-sized microstructure that is difficult to produce by a conventional method.

Abstract: The present invention relates to a modified siloxane resin, a crosslinked modified siloxane resin, and a method for preparing the crosslinked resin. More specifically, the present invention relates to a modified siloxane resin, a crosslinked modified siloxane resin with excellent superhydrophobicity obtained by dual curing of the resin, and a method for preparing the crosslinked resin. The use of the modified siloxane resin according to the present invention allows the crosslinked modified siloxane resin to have excellent superhydrophobicity and high hardness. The water repellency of the crosslinked resin can be appropriately controlled by varying the amount of the siloxane resin mixed.

Abstract: The present invention relates to: a pharmaceutical composition for preventing or treating vascular or cardiac valvular calcification, containing a thiamine derivative or a pharmaceutically acceptable salt thereof; and a food composition for alleviating vascular or cardiac valvular calcification, containing a thiamine derivative or a salt thereof, and the compositions of the present invention can be effectively used for a use of preventing, treating or alleviating vascular or cardiac valvular calcification.

Abstract: The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor as an active ingredient.

Abstract: Disclosed are a recombinant poly(ethylene terephthalate) hydrolase (PETase) expression vector, a recombinant mono(2-hydroxyethyl)terephthalate hydrolase (MHETase) expression vector, a strain for producing each of the recombinant PETase and MHETase containing each of the vectors, and a method for degrading a plastics using each of the recombinant PETase and MHETase expressed therefrom. When the recombinant hydrolases, that is, PETase and MHETase are used together, high enzymatic activity may be sustained for a long time to completely degrade the PET.

Abstract: Provided is a method for preventing and/or treating cancer, the method including administering to a subject a composition containing manassantin and an immune checkpoint inhibitor, or manassantin A and an epithelial growth factor receptor inhibitor, as active ingredients. The composition of the presently claimed subject matter is expected to be effectively used to suppress, through co-administration, the proliferation, metastasis, relapse, or resistance to anticancer therapy of various solid cancers.

Abstract: The present invention relates to a peptide bound to PD-L1 and uses for cancer immunotherapy and anticancer using the same, and the peptide of the present invention specifically binds to PD-L1 and inhibits it, thereby activating the function of immune cells against cancer cells and exhibiting anticancer effects. The peptides of the present invention selected two peptides (PD-L1Pep-1 and PD-L1Pep-2) that bind well to cells with high expression of human PD-L1 protein using phage peptide display technology and it was confirmed that it inhibits its function by binding to PD-L1 in humans and mice. The peptide of the present invention showed an effect similar level to that of an antibody and is relatively stable in blood, indicating a high potential as a cancer immunotherapy in the future.